RxDoctor Payments Data

Mohammad Shafi, MD

Nephrology · Joliet, ILNPI 1528052792

Payments from drug & device makers

$2,815in general payments, 2019–2025

Across 109 payments — averaging $25.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$436
  • Travere Therapeutics, Inc.$367
  • Otsuka America Pharmaceutical, Inc.$336
  • AstraZeneca$307
  • Fresenius USA Marketing, Inc.$267
  • Nxstage Medical, Inc.$153
  • plus $950 from 21 others

What the payments were for

  • Food & beverage$2,66995%
  • Education$1475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,815 in reported general payments places this provider in the 70th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$90,524
Medicare patients
69
Services billed
674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$54,328
FarxigaDapagliflozin Propanediol69$49,498
VelphoroSucroferric Oxyhydroxide12$30,256
JardianceEmpagliflozin34$25,717
MounjaroTirzepatide22$25,272
JanuviaSitagliptin Phosphate15$7,382
EliquisApixaban13$7,281
VeltassaPatiromer Calcium Sorbitex13$6,150
Sevelamer Carbonate11$872
Calcitriol49$501
Amlodipine Besylate63$340
Lisinopril43$287
Hydralazine Hcl27$276
Felodipine ErFelodipine13$276
Furosemide57$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$59$54,32855 claims
AstraZenecaFarxiga$307$49,49869 claims
Fresenius USA Marketing, Inc.Velphoro$267$30,25612 claims
Boehringer IngelheimJardiance$15$25,71734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 524 nephrology providers in Illinois.

Other nephrology in Joliet

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →